AbbVie Aktie News

AbbVie's third-quarter results exceeded Wall Street's expectations. Sales from the pharmaceutical company's three top drugs are soaring.

AbbVie has performed exceedingly well over the past 12 years. The company still has many of the traits that led to that result.

AbbVie Inc. (ABBV) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Data being presented showcases AbbVie's breadth and depth of research across a range of therapeutic modalities such as T-Cell Engagers, BCL-2 Inhibitors and Antibody-Drug Conjugates for a spectrum of difficult-to-treat blood cancers NORTH CHICAGO, Ill. , Dec. 2, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it will unveil new data at the 2025 American Society of Hematology (ASH) Cong...

Pfizer's strategy that will help it rebound from recent struggles is in full motion. It says a lot that the company continues to grow its dividend through tough times.

AbbVie (ABBV) remains a "Strong Buy" due to robust growth in immunology and neuroscience portfolios, offsetting Humira's decline. ABBV's oncology segment is poised for expansion with trispecific antibody ISB 2001 for relapsed/refractory multiple myeloma and Epkinly's third FDA approval. Epkinly's rapid sales growth and multiple ongoing phase 3 studies signal further upside potential in ABBV's o...

The stocks listed below yield between 2.7% and 3.5%. They are in different sectors of the economy and can help diversify your portfolio while also generating plenty of recurring cash flow.

The ProShares S&P 500 Dividend Aristocrats ETF (NOBL) has underperformed the SPDR S&P 500 ETF (SPY) year-to-date, but November shows a reversal. Several Dividend Aristocrats, including CAH, CAT, CHRW, and ALB, have posted double-digit gains in 2025, while others lag behind. Dividend growth among Aristocrats averages 5.46% for 2025, with most constituents announcing increases, though growth is s...